Biotech Values

[Biopharm investor]

enoxaparin competition

In light of the recent discussions here I jumped over to read some of the information on MNTA. The post to which I am replying states:

"A key issue from a valuation standpoint is whether MNTA/NVS obtains the only FDA approval of a generic Lovenox or whether the competitors—Teva and Amphastar—also get approval."

At least four companies have filed ANDAs with Paragraph IV certification for generic versions of Lovenox (enoxaparin sodium): Teva, Amphastar, MNTA/Sandoz, and Hospira.